# A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects

> **NCT02275481** · PHASE4 · TERMINATED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 66 (actual)

## Conditions studied

- Chronic Obstructive Pulmonary Disease (COPD)

## Interventions

- **DRUG:** Arformoterol tartrate inhalation solution
- **DRUG:** Tiotropium

## Key facts

- **NCT ID:** NCT02275481
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2014-11
- **Primary completion:** 2016-09-14
- **Final completion:** 2016-09-14
- **Target enrollment:** 66 (ACTUAL)
- **Why stopped:** lack of enrollment
- **Last updated:** 2018-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02275481

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02275481, "A Study of Arformoterol Tartrate Inhalation Solution and Tiotropium Bromide on Re-hospitalization in Chronic Obstructive Pulmonary Disease (COPD) Subjects". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02275481. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*